Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas

Primary High-grade Neuroendocrine Carcinoma of the Esophagus

(2013) Qin Huang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical view

(2012) Nicola Fazio et al.   CANCER TREATMENT REVIEWS

Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas

(2012) K. Nakano et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

(2011) Natsuko Tsuda Okita et al.   Gastric Cancer

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

(2010) Martin B Niederle et al.   ENDOCRINE-RELATED CANCER

Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas

(2010) S. Iwasa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY